HARVARD BIOSCIENCE INC (HBIO) Fundamental Analysis & Valuation

NASDAQ:HBIO • US4169062043

Current stock price

6.78 USD
+0.09 (+1.35%)
Last:

This HBIO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. HBIO Profitability Analysis

1.1 Basic Checks

  • HBIO had negative earnings in the past year.
  • In the past year HBIO had a positive cash flow from operations.
  • In the past 5 years HBIO always reported negative net income.
  • In the past 5 years HBIO always reported a positive cash flow from operatings.
HBIO Yearly Net Income VS EBIT VS OCF VS FCFHBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M

1.2 Ratios

  • HBIO has a Return On Assets of -70.81%. This is amonst the worse of the industry: HBIO underperforms 91.07% of its industry peers.
  • HBIO has a worse Return On Equity (-412.84%) than 89.29% of its industry peers.
Industry RankSector Rank
ROA -70.81%
ROE -412.84%
ROIC N/A
ROA(3y)-27.7%
ROA(5y)-17.96%
ROE(3y)-145.7%
ROE(5y)-90.12%
ROIC(3y)N/A
ROIC(5y)N/A
HBIO Yearly ROA, ROE, ROICHBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200 -300 -400

1.3 Margins

  • Looking at the Gross Margin, with a value of 57.67%, HBIO is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
  • HBIO's Gross Margin has been stable in the last couple of years.
  • HBIO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.67%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.6%
GM growth 5Y0.3%
HBIO Yearly Profit, Operating, Gross MarginsHBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 -60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. HBIO Health Analysis

2.1 Basic Checks

  • HBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, HBIO has more shares outstanding
  • HBIO has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for HBIO is higher compared to a year ago.
HBIO Yearly Shares OutstandingHBIO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M
HBIO Yearly Total Debt VS Total AssetsHBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -2.03, we must say that HBIO is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -2.03, HBIO is not doing good in the industry: 82.14% of the companies in the same industry are doing better.
  • HBIO has a debt to FCF ratio of 7.37. This is a slightly negative value and a sign of low solvency as HBIO would need 7.37 years to pay back of all of its debts.
  • The Debt to FCF ratio of HBIO (7.37) is better than 64.29% of its industry peers.
  • HBIO has a Debt/Equity ratio of 2.61. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 2.61, HBIO is doing worse than 85.71% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 2.61
Debt/FCF 7.37
Altman-Z -2.03
ROIC/WACCN/A
WACC11.48%
HBIO Yearly LT Debt VS Equity VS FCFHBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M 60M 80M

2.3 Liquidity

  • HBIO has a Current Ratio of 2.20. This indicates that HBIO is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of HBIO (2.20) is comparable to the rest of the industry.
  • A Quick Ratio of 1.25 indicates that HBIO should not have too much problems paying its short term obligations.
  • HBIO's Quick ratio of 1.25 is on the low side compared to the rest of the industry. HBIO is outperformed by 73.21% of its industry peers.
Industry RankSector Rank
Current Ratio 2.2
Quick Ratio 1.25
HBIO Yearly Current Assets VS Current LiabilitesHBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. HBIO Growth Analysis

3.1 Past

  • The earnings per share for HBIO have decreased strongly by -133.33% in the last year.
  • HBIO shows a decrease in Revenue. In the last year, the revenue decreased by -8.06%.
  • The Revenue has been decreasing by -3.25% on average over the past years.
EPS 1Y (TTM)-133.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)-8.06%
Revenue growth 3Y-8.59%
Revenue growth 5Y-3.25%
Sales Q2Q%-3.34%

3.2 Future

  • HBIO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 55.18% yearly.
  • Based on estimates for the next years, HBIO will show a small growth in Revenue. The Revenue will grow by 5.99% on average per year.
EPS Next Y-644.6%
EPS Next 2Y55.18%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.49%
Revenue Next 2Y5.99%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
HBIO Yearly Revenue VS EstimatesHBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
HBIO Yearly EPS VS EstimatesHBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 2

More info and screens

Find the best growth stocksShow best growing peers

3

4. HBIO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for HBIO. In the last year negative earnings were reported.
  • Also next year HBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HBIO Price Earnings VS Forward Price EarningsHBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

  • 94.64% of the companies in the same industry are more expensive than HBIO, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, HBIO is valued cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 6.23
EV/EBITDA 10.42
HBIO Per share dataHBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • A more expensive valuation may be justified as HBIO's earnings are expected to grow with 55.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y55.18%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HBIO Dividend Analysis

5.1 Amount

  • HBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HBIO Fundamentals: All Metrics, Ratios and Statistics

HARVARD BIOSCIENCE INC

NASDAQ:HBIO (4/23/2026, 5:20:02 PM)

6.78

+0.09 (+1.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-12
Earnings (Next)04-30
Inst Owners51.08%
Inst Owner Change28.36%
Ins Owners6.74%
Ins Owner Change1.48%
Market Cap30.31M
Revenue(TTM)86.55M
Net Income(TTM)-56.70M
Analysts80
Price Target6.12 (-9.73%)
Short Float %N/A
Short Ratio0.25
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-100%
Min EPS beat(2)-100%
Max EPS beat(2)-100%
EPS beat(4)2
Avg EPS beat(4)-30.64%
Min EPS beat(4)-100%
Max EPS beat(4)75.49%
EPS beat(8)3
Avg EPS beat(8)-49.3%
EPS beat(12)4
Avg EPS beat(12)-42.66%
EPS beat(16)5
Avg EPS beat(16)-40.85%
Revenue beat(2)2
Avg Revenue beat(2)0.84%
Min Revenue beat(2)0.73%
Max Revenue beat(2)0.94%
Revenue beat(4)3
Avg Revenue beat(4)2.78%
Min Revenue beat(4)-1.72%
Max Revenue beat(4)11.18%
Revenue beat(8)3
Avg Revenue beat(8)-3.14%
Revenue beat(12)4
Avg Revenue beat(12)-3.71%
Revenue beat(16)4
Avg Revenue beat(16)-4.33%
PT rev (1m)200%
PT rev (3m)200%
EPS NQ rev (1m)-1110%
EPS NQ rev (3m)-12000%
EPS NY rev (1m)-253.68%
EPS NY rev (3m)-1636.84%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.24%
Revenue NY rev (1m)-0.56%
Revenue NY rev (3m)-4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.35
P/FCF 6.23
P/OCF 4.5
P/B 2.21
P/tB N/A
EV/EBITDA 10.42
EPS(TTM)-0.2
EYN/A
EPS(NY)-1.49
Fwd EYN/A
FCF(TTM)1.09
FCFY16.06%
OCF(TTM)1.51
OCFY22.2%
SpS19.36
BVpS3.07
TBVpS-0.77
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -70.81%
ROE -412.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.67%
FCFM 5.62%
ROA(3y)-27.7%
ROA(5y)-17.96%
ROE(3y)-145.7%
ROE(5y)-90.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.6%
GM growth 5Y0.3%
F-Score4
Asset Turnover1.08
Health
Industry RankSector Rank
Debt/Equity 2.61
Debt/FCF 7.37
Debt/EBITDA 6.54
Cap/Depr 31.34%
Cap/Sales 2.15%
Interest Coverage N/A
Cash Conversion 122.66%
Profit Quality N/A
Current Ratio 2.2
Quick Ratio 1.25
Altman-Z -2.03
F-Score4
WACC11.48%
ROIC/WACCN/A
Cap/Depr(3y)36.65%
Cap/Depr(5y)29.73%
Cap/Sales(3y)2.56%
Cap/Sales(5y)2.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-133.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y-644.6%
EPS Next 2Y55.18%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-8.06%
Revenue growth 3Y-8.59%
Revenue growth 5Y-3.25%
Sales Q2Q%-3.34%
Revenue Next Year3.49%
Revenue Next 2Y5.99%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y91.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year117.79%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y366.92%
FCF growth 3YN/A
FCF growth 5Y-9.87%
OCF growth 1Y367.29%
OCF growth 3Y80.2%
OCF growth 5Y-6.33%

HARVARD BIOSCIENCE INC / HBIO Fundamental Analysis FAQ

What is the ChartMill fundamental rating of HARVARD BIOSCIENCE INC (HBIO) stock?

ChartMill assigns a fundamental rating of 3 / 10 to HBIO.


Can you provide the valuation status for HARVARD BIOSCIENCE INC?

ChartMill assigns a valuation rating of 3 / 10 to HARVARD BIOSCIENCE INC (HBIO). This can be considered as Overvalued.


What is the profitability of HBIO stock?

HARVARD BIOSCIENCE INC (HBIO) has a profitability rating of 2 / 10.


Can you provide the expected EPS growth for HBIO stock?

The Earnings per Share (EPS) of HARVARD BIOSCIENCE INC (HBIO) is expected to decline by -644.6% in the next year.